FDA and Health Care

LEADERS

Overview

Gibson, Dunn & Crutcher’s FDA and Health Care Practice Group counsels clients in U.S. governmental investigations, U.S. Food and Drug Administration (FDA) regulatory and litigation matters, mergers and acquisitions, data privacy, all areas of litigation, including mass tort and consumer class actions, product liability, off-label marketing, the Employee Retirement Income Security Act (ERISA) and patent, and in all other health industry matters.

Our specific areas of focus include:

  • Governmental investigations and related litigation
  • FDA regulatory and litigation matters
  • Medical device patent and other litigation
  • Mass tort and product liability litigation across the United States
  • Consumer class actions
  • ERISA litigation
  • Antitrust and securities litigation
  • Public and private equity mergers and acquisitions
  • Financings
  • Securities offerings
  • Licensing, development and distribution arrangements
  • General corporate governance
  • Board of directors and special board committee matters

The FDA and Health Care group’s client work includes compliance, investigatory, litigation and corporate matters.  Our lawyers work on U.S. and international fronts achieving successful outcomes for our clients including cutting-edge litigation and precedent-setting appeals before the U.S. Supreme Court.

The FDA and Health Care practice is cross-disciplinary, drawing on Gibson Dunn’s firmwide capabilities and resources.  Our lawyers address issues including privacy and data breaches, intellectual property licensing and corporate governance.  Corporate and transactional work includes representing issuers, investment banks in their capacity as underwriters, placement agents and financial advisers.

Our group members are experienced in civil and criminal investigations and also litigation under the U.S. False Claims Act.  We bring a unique breadth of familiarity and talent to handling complex enforcement matters and conducting sensitive, cost-effective internal investigations.  We bring that same experience and perspective to a wide range of compliance counseling.

EXPERIENCE & RECENT REPRESENTATIONS

  • Secured dismissal for Sanofi of a novel False Claims Act lawsuit by qui tam relator Amphastar Pharmaceuticals, Inc.  The suit, which related to U.S. federal and state reimbursements for Sanofi’s blockbuster anticoagulant drug Lovenox®, sought damages and fines exceeding $5 billion.  After a four-day evidentiary hearing, the Central District of California found that rather than independently developing a generic version of Lovenox®, Amphastar had copied the teachings of Sanofi’s patent.  As a result, the court determined that Amphastar had failed to prove that it qualified as an “original source” of the information underlying its allegations, a jurisdictional requirement under the False Claims Act for suits based on publicly disclosed information.  On that basis, the suit was dismissed.
  • Secured appellate victory for Momence Meadows Nursing Center, Inc. when the Seventh Circuit vacated a $9 million jury verdict in a False Claims Act suit, rejected a cross-appeal seeking to impose an additional $19 million in penalty fines, and remanded with instructions to enter judgment for Momence, holding that relators’ claims failed as a matter of law.  Relators had alleged that Momence submitted thousands of false claims to Medicare and Medicaid in connection with its Illinois skilled nursing facility and was liable under “worthless services” and “false certification” theories.  In reasoning with broad implications for the healthcare industry, the court rejected “worthless services” liability with the explanation that “[i]t is not enough to offer evidence that the defendant provided services that are worth some amount less than the services paid for;” rather, liability cannot be established unless the services are “[t]ruly worthless.”
  •  Obtained summary judgment for the former general counsel and chief compliance officer of Tenet Healthcare in an action brought by the U.S. Department of Justice, alleging personal liability under the False Claims Act for alleged Stark Law violations by a Tenet hospital in Florida.  This case generated substantial attention within the health care industry due to its unprecedented attempt to hold in-house counsel personally liable for alleged wrongdoing by a subsidiary entity.
  • Successfully defended Tenet Healthcare in a number of False Claims Act cases brought by the government and/or qui tam plaintiffs involving issues such as coding and whether physician contracts were in violation of the Stark Law.  We have also represented Tenet in antitrust representations on matters before the Federal Trade Commission and Department of Justice, and numerous other U.S. state and federal investigations.
  • Secured summary judgment of non-infringement for Medtronic, Inc. in the Western District of New York.  Plaintiff Medgraph, Inc. alleged that use of Medtronic’s blood glucose monitors and associated software indirectly infringed method claims and directly infringed a system claim in Medgraph’s patents related to remote patient monitoring.  Gibson Dunn successfully argued that because multiple independent actors were required to perform the steps of the asserted method claims, there could be no direct infringement – and thus no indirect infringement – under the Federal Circuit’s single-actor rule.  The parties submitted several rounds of briefing while the single-actor rule was challenged in the Federal Circuit and the U.S. Supreme Court before being upheld by the Federal Circuit’s 2015 Akamai Tech., Inc. v. Limelight Networks, Inc.decision.  Gibson Dunn also convinced the district court that Medtronic’s accused system lacked key elements of the asserted system claim as it would be understood by a person of ordinary skill in the art.
  • Obtained summary judgment of non-infringement in favor of St. Jude Medical in a suit in the Southern District of Florida accusing St. Jude’s implantable pacemakers and defibrillators of infringing a patent directed to wireless networking and communication protocols.  Shortly after St. Jude was sued, Gibson Dunn won a motion to dismiss under the recently enacted Leahy-Smith America Invents Act, as the plaintiff had improperly joined St. Jude with one of its primary competitors.  In a separate case then filed by the plaintiff against St. Jude, Gibson Dunn first obtained a favorable claim construction ruling, and then a favorableDaubert ruling, striking the plaintiff’s entire damages expert report, which sought $798 million in damages.  We then won summary judgment of non-infringement on all asserted claims.
  • Secured unanimous U.S. Supreme Court victory for Nautilus, Inc. when the Court struck down the Federal Circuit’s test for patent indefiniteness, holding that the “insolubly ambiguous” standard tolerated too much ambiguity in patent claims.  The decision makes it easier to prove a patent claim invalid for indefiniteness under 35 U.S.C. §112, ¶2.  The Circuit had found a patent assigned to Biosig and directed to a heart-rate monitor for use during exercise not indefinite.  After certiorari was granted, Gibson Dunn was retained as co-counsel to Nautilus and successfully urged rejection of the Federal Circuit’s standard   The Supreme Court adopted a more exacting definiteness standard.
  • Secured dismissal with prejudice of trademark and copyright claims in the Western District of Pennsylvania for CNS Vital Signs, one of the leading sellers of neurocognitive testing software.  CNS’ chief rival, Impact Applications, Inc., alleged that CNS’ concussion tests and their marketing infringed Impact’s trademarks, copyrights and state law rights.  In response to Gibson Dunn’s motion to dismiss, a U.S. Magistrate Judge recommended that it be granted but that Impact be given leave to replead.  Gibson Dunn briefed objections and advocated for dismissal with prejudice, which the court’s chief judge subsequently granted.
  • Secured a significant victory for Aetna, Inc. in a long-running class action when the District of New Jersey dismissed claims under RICO, the Sherman Act, and various ERISA and state law theories.  The court agreed with virtually every argument advanced by Gibson Dunn in dismissing 13 of the 15 causes of action.  The case, filed nearly eight years earlier, alleged that Aetna had systematically underpaid benefits to health plan members using a rigged database of provider charges.  It grew to a multidistrict class action with claims brought by health care plan members, health care providers, and medical societies against Aetna and its alleged co-conspirators.  Gibson Dunn filed multiple rounds of motions to dismiss, completed fact discovery, and completed multiple class certification briefings.
  • Won complete victory for St. Joseph Health System by securing dismissal of a putative data breach class action seeking $33 million in statutory damages.  Asserting claims under California’s Confidentiality of Medical Information Act (CMIA) and the common law, including the right to privacy and negligence, plaintiff alleged that St. Joseph had lost possession of the confidential medical information of more than 33,000 patients at its Santa Rosa hospital.  The California Superior Court agreed with Gibson Dunn that plaintiff had not alleged sufficient facts to proceed and dismissed with leave to amend.  Plaintiff subsequently agreed to voluntarily dismiss his claims with prejudice.
  • Won dismissal in the Western District of Washington of a putative class action against Microsoft Corporation and its health plan.  Plaintiff alleged that the plan’s exclusion of benefits for mental health treatment in residential treatment centers violated the U.S. Mental Health Parity and Addiction Equity Act of 2008, which required ERISA-governed health plans to provide mental health benefits “in parity” with medical and surgical benefits.  The court agreed with Gibson Dunn that neither the statute nor its implementing regulations prohibited the residential treatment exclusion.
  • Won dismissal for Aetna Life Insurance Company in the Northern District of California of a putative nationwide class action alleging systematic and wrongful denial of claims for mental health care benefits provided at residential treatment facilities.  The plaintiffs claimed that their residential treatment should have been covered because of the facilities’ licensing under state law, but the court held that plaintiffs had failed to satisfy the second requirement contained in their plans, that of 24/7 staffing by licensed behavioral health care providers.  Because plaintiffs neither alleged satisfaction of this criteria nor could plead their way around it based on their arguments asserted in response to the motion to dismiss, the court held that they had failed to state a claim upon which relief could be granted.
  • Won denial of class certification for Aetna, Inc. in the Northern District of California, of two putative classes of plaintiffs challenging the insurer’s methodology for making coverage determinations regarding mental health benefits involving residential treatment facilities.  The court concluded that any common issues were not central to the validity of plaintiffs’ claims, and therefore failed to satisfy the commonality requirement of Federal Rule of Civil Procedure 23.  This victory was of particular importance as it foreclosed the possibility of classwide treatment of medical necessity determinations, considered by Aetna to be inherently individualized, and established needed helpful precedent.
  • Secured a significant victory for Aetna, Inc. in a long-running class action when the District of New Jersey dismissed claims under RICO, the Sherman Act, and various ERISA and state law theories.  The court agreed with virtually every argument advanced by Gibson Dunn in dismissing 13 of the 15 causes of action.  The case, filed nearly eight years earlier, alleged that Aetna had systematically underpaid benefits to health plan members using a rigged database of provider charges.  It grew to a multidistrict class action with claims brought by health care plan members, health care providers, and medical societies against Aetna and its alleged co-conspirators.  Gibson Dunn filed multiple rounds of motions to dismiss, completed fact discovery, and completed multiple class certification briefings.
  • Won complete victory for St. Joseph Health System by securing dismissal of a putative data breach class action seeking $33 million in statutory damages.  Asserting claims under California’s Confidentiality of Medical Information Act (CMIA) and the common law, including the right to privacy and negligence, plaintiff alleged that St. Joseph had lost possession of the confidential medical information of more than 33,000 patients at its Santa Rosa hospital.  The California Superior Court agreed with Gibson Dunn that plaintiff had not alleged sufficient facts to proceed and dismissed with leave to amend.  Plaintiff subsequently agreed to voluntarily dismiss his claims with prejudice.
  • Won dismissal in the Western District of Washington of a putative class action against Microsoft Corporation and its health plan.  Plaintiff alleged that the plan’s exclusion of benefits for mental health treatment in residential treatment centers violated the U.S. Mental Health Parity and Addiction Equity Act of 2008, which required ERISA-governed health plans to provide mental health benefits “in parity” with medical and surgical benefits.  The court agreed with Gibson Dunn that neither the statute nor its implementing regulations prohibited the residential treatment exclusion.
  • Won dismissal for Aetna Life Insurance Company in the Northern District of California of a putative nationwide class action alleging systematic and wrongful denial of claims for mental health care benefits provided at residential treatment facilities.  The plaintiffs claimed that their residential treatment should have been covered because of the facilities’ licensing under state law, but the court held that plaintiffs had failed to satisfy the second requirement contained in their plans, that of 24/7 staffing by licensed behavioral health care providers.  Because plaintiffs neither alleged satisfaction of this criteria nor could plead their way around it based on their arguments asserted in response to the motion to dismiss, the court held that they had failed to state a claim upon which relief could be granted.
  • Won denial of class certification for Aetna, Inc. in the Northern District of California, of two putative classes of plaintiffs challenging the insurer’s methodology for making coverage determinations regarding mental health benefits involving residential treatment facilities.  The court concluded that any common issues were not central to the validity of plaintiffs’ claims, and therefore failed to satisfy the commonality requirement of Federal Rule of Civil Procedure 23.  This victory was of particular importance as it foreclosed the possibility of classwide treatment of medical necessity determinations, considered by Aetna to be inherently individualized, and established needed helpful precedent.
  • Defeated a motion for preliminary injunction in the Western District of Texas on behalf of the American College of Allergy, Asthma & Immunology, the Joint Council for Allergy, Asthma & Immunology, and numerous individual defendants.  This antitrust lawsuit concerned joint marketing and advocacy campaigns to physicians and health insurance companies undertaken by the defendants regarding proper standards of care in the practice of allergy therapy, which the plaintiffs asserted violated section 1 of the Sherman Act and Texas state law.  The injunction would have effectively enjoined any and all communication by the defendants regarding health and safety concerns raised by certain allergy therapy practitioners.  The court agreed with Gibson Dunn that the plaintiffs had not established a likelihood of success on the merits on their price-fixing, group boycott, and Texas state law claims.
  • Acted as antitrust counsel to Tenet Healthcare Corporation in connection with its $131 million acquisition of Emanuel Medical Center.  We secured Federal Trade Commission clearance for the transaction, making Tenet the largest provider of hospital services in California’s Central Valley.  Gibson Dunn, retained after the FTC issued a Second Request, successfully argued that the acquisition was procompetitive, and the agency closed its 10-month investigation.
  • Obtained a victory on behalf of the directors of Allergan, Inc. in the Supreme Court of Delaware in derivative lawsuits.  The substantively identical lawsuits against Allergan’s directors were filed in both California and Delaware.  The court agreed with Gibson Dunn that a previous California dismissal precluded further proceedings in Delaware, holding that the preclusion law of California, not of Delaware, must be applied; and that under established California preclusion law, the dismissal of one shareholder derivative complaint precludes complaints by other shareholders on the same allegations and theories.
  • Tenet Healthcare in its:
    • Formation of a historic $2 billion joint venture resulting in the largest ever acquisition of outpatient surgery centers
    • $4.3 billion acquisition of Vanguard Health Systems, an operator of acute care and specialty hospitals.  The transaction made Tenet the No. 1 or No. 2 hospital system in 19 key markets
  • Cardinal Health, Inc. in its:
    • $1.5 billion public offering of notes issued, in part, to finance the acquisition of certain assets of Johnson & Johnson’s Cordis business
    • $1.2 billion public offering of notes and redemption of outstanding notes
  • Kindred Healthcare, as special counsel in its $1.8 billion unsolicited acquisition of Gentiva Health Services, a home health care and hospice services firm.
  • Covidien, in its:
    • $1.5 billion refinancing of a senior revolving credit facility
    • Issuance of $750 million of senior notes
  • Northstar Healthcare in its $640 million acquisition and financing of a portfolio of 16 continuing care retirement communities in 11 U.S. states.
  • St. Jude Medical, in its:
    • $375 million acquisition of the remaining 81% ownership of CardioMEMS, a medical device manufacturer
    • Acquisition of Endosense SA, a Switzerland-based medical device company, for up to $331 million
    • $200 million acquisition of NeuroTherm, a medical device company
  • Represented a coalition of manufacturers in a medical device reclassification matter and public hearing before the FDA.  The coalition prevailed.
  • Served as FDA regulatory advisor to a major medical device manufacturer during False Claims Act litigation involving allegations of off-label promotion.  The case was dismissed.
  • Conducted an enterprise-wide risk assessment of a Fortune 50 company’s health care communications, marketing and social media practices.
  • Advised a Fortune 50 company on the premarket pathway and clinical testing strategy for its first mobile health medical device.  The FDA cleared the device for marketing.
  • Counseled companies through appeals of FDA decisions and the dispute resolution process, including issues relating to premarket pathways and product classifications.
  • Evaluated complaint-handling and adverse event reporting practices, and prepared corporate policies and procedures governing medical device reporting (MDR).
  • Led 510(k) audits of modifications to medical devices and “letters to file.”
  • Counseled companies on FDA and FTC regulatory strategies for digital health technologies, including mobile apps and telehealth devices.
  • Conducted training for new FDA personnel and companies on FDA law and regulation.

RECENT PUBLICATIONS

FDA Releases Draft Guidance Proposing a Significant Expansion of the Abbreviated 510(k) Pathway for Medical Devices

-April 17, 2018

Federal Circuit Update (March 2018)

-March 29, 2018

2017 Year-End FDA and Health Care Compliance and Enforcement Update – Drugs and Devices

-January 24, 2018

2017 Year-End False Claims Act Update

-January 5, 2018

Elder Abuse Reporting Under Scrutiny

-December 1, 2017

Federal Circuit Update (November 2017)

-November 30, 2017

Federal Circuit Update (September 2017)

-September 26, 2017

2017 Mid-Year FDA and Health Care Compliance and Enforcement Update – Providers

-September 4, 2017

Webcast: 2017 Mid-Year Update: The False Claims Act and Health Care Providers

-August 30, 2017

2017 Mid-Year FDA and Health Care Compliance and Enforcement Update – Drugs and Devices

-August 25, 2017

Cybersecurity & Data Privacy: An Overview for Health Care, Pharmaceutical, and Biotech Companies

-August 8, 2017

Webcast: 2017 Mid-Year Update: The False Claims Act and Drug and Device Manufacturers

-August 2, 2017

Federal Circuit Update (July 2017)

-July 31, 2017

TC Heartland—A Renewed Opportunity to Challenge Venue in Patent Infringement Cases

-June 15, 2017

Federal Circuit Update (March 2017)

-March 28, 2017

2016 Year-End Health Care Compliance and Enforcement Update – Providers

-February 15, 2017

Federal Circuit Update (January 2017)

-January 26, 2017

2016 Year-End FDA and Health Care Compliance and Enforcement Update – Drugs and Devices

-January 12, 2017

2016 Year-End False Claims Act Update

-January 5, 2017

Using and Defending Against Statistical Sampling in False Claims Act Cases

-January 1, 2017

2015/2016 Federal Circuit Year in Review

-December 7, 2016

The Trump Presidency: Selected Initial Observations and Considerations

-November 15, 2016

FCA Liability after Escobar: Challenges and Opportunities for Device Companies

-October 27, 2016

Compliance Perspectives on the Developing Contours of the PSQIA

-October 3, 2016

Federal Circuit Update (September 2016)

-September 29, 2016

Webcast: Hot Topics in Fraud and Abuse Enforcement Involving Health Care Providers

-September 22, 2016

2016 Mid-Year Health Care Compliance and Enforcement Update – Providers

-August 2, 2016

Evaluating U.S. Fraud and Abuse Compliance Controls, Including Corporate Integrity Agreement Provisions, for a Global Anti-Corruption Compliance Program

-August 1, 2016

2016 Mid-Year FDA and Health Care Compliance and Enforcement Update – Drugs and Devices

-July 27, 2016

2016 Mid-Year False Claims Act Update

-July 7, 2016

Federal Circuit Update (March 2016)

-March 24, 2016

2015 Year-End Health Care Compliance and Enforcement Update – Providers

-February 18, 2016

Federal Circuit Update (January 2016)

-January 27, 2016

2015 Year-End FDA and Health Care Compliance and Enforcement Update – Drugs and Devices

-January 19, 2016

2015 Year-End False Claims Act Update

-January 6, 2016

2015 Year-End Update on Corporate Non-Prosecution Agreements (NPAs) and Deferred Prosecution Agreements (DPAs)

-January 5, 2016

Compliance Implications of the Rise of False Claims Act Cases Based on the 60-Day Rule

-December 1, 2015

M&A Report – Depomed Decision Highlights Importance of Careful Monitoring of M&A Non-Disclosure & Use Obligations

-November 20, 2015

Another Successful Challenge to Restrictions on Off-Label Promotion

-August 13, 2015

RICO Suits Challenge Off-Label Drug Marketing

-August 3, 2015

2015 Mid-Year FDA and Health Care Compliance and Enforcement Update – Drugs and Devices

-July 16, 2015

2015 Mid-Year Update on Corporate Non-Prosecution Agreements (NPAs) and Deferred Prosecution Agreements (DPAs)

-July 8, 2015

2015 Mid-Year False Claims Act Update

-July 8, 2015

A Practical Guide to the Use of the Commissioned Public Report as an Effective Crisis-Management Tool

-June 12, 2015

U.S. SEC Adopts Final Rules Implementing “Regulation A+” Offering Exemption for Offerings of up to $50 Million

-April 22, 2015

U.S. Supreme Court Issues Long-Awaited Decision in Omnicare, Resolving Circuit Split Regarding Opinion Statement Liability under Section 11 of Securities Act of 1933

-March 25, 2015

2014 Year-End FDA Compliance and Enforcement Update – Food and Dietary Supplements

-March 2, 2015

Cybersecurity and Data Privacy Outlook and Review: 2015

-February 17, 2015

2014 Year-End Health Care Compliance and Enforcement Update – Providers

-January 14, 2015

2014 Year-End FDA and Health Care Compliance and Enforcement Update – Drugs and Devices

-January 14, 2015

2014 Year-End False Claims Act Update

-January 7, 2015

2014 Year-End Update on Corporate Non-Prosecution Agreements (NPAs) and Deferred Prosecution Agreements (DPAs)

-January 6, 2015

Health regulation makes for strange bedfellows

-November 16, 2014

2014 Mid-Year False Claims Act Update

-July 9, 2014

2014 Mid-Year Update on Corporate Non-Prosecution Agreements (NPAs) and Deferred Prosecution Agreements (DPAs)

-July 8, 2014

To Institute or Not to Institute IPR? That Question Is Not Immediately Reviewable by the Federal Circuit

-May 5, 2014

2013 Year-End Update on Corporate Non-Prosecution Agreements and Deferred Prosecution Agreements (Part 2)

-May 1, 2014

2013 Year-End Update on Corporate Non-Prosecution Agreements and Deferred Prosecution Agreements (Part 1)

-April 1, 2014

U.S. Supreme Court Places the Burden of Proving Infringement on Patent Holders in Declaratory Judgment Actions

-January 23, 2014

2013 Year-End False Claims Act Update

-January 8, 2014

2013 Year-End Update on Corporate Non-Prosecution Agreements (NPAs) and Deferred Prosecution Agreements (DPAs)

-January 7, 2014

Antitrust Scrutiny of Pharmaceutical Product Hopping

-October 1, 2013

2013 Mid-Year False Claims Act Update

-July 10, 2013

2013 Mid-Year Update on Corporate Deferred Prosecution Agreements (DPAs) and Non-Prosecution Agreements (NPAs)

-July 9, 2013

United States Sentencing Commission Adopts Greater Penalties for Fraud Offenses and Fixes Anomaly in Sentences for Tax Crimes

-April 23, 2013

For Skilled Nursing and Nursing Facilities, Compliance Counts

-April 1, 2013

The European Commission Launches a Consultation Process in Relation to the Manufacturing Practices for Medicinal Products

-February 27, 2013

2012 Year-End Health Care Enforcement Update

-February 22, 2013

Off-Label Promotion: Still a Crime?

-January 14, 2013

2012 Year-End False Claims Act Update

-January 8, 2013

2012 Year-End Update on Corporate Deferred Prosecution Agreements (DPAs) and Non-Prosecution Agreements (NPAs)

-January 3, 2013

The End of Off-Label Prosecutions? The Second Circuit Rules That a Pharmaceutical Sales Representative’s Criminal Conviction for Off-Label Promotion Violates the First Amendment

-December 4, 2012

With a Scalpel Not a Sledgehammer: Resolving FDCA Investigations through Deferred Prosecution and Non-Prosecution Agreements

-November 1, 2012

U.S. Agencies Release Guidance on Shared Responsibility Employer Penalties and Waiting Period Limitations under the Affordable Care Act

-October 25, 2012

2012 Mid-Year False Claims Act Update

-July 12, 2012

2012 Mid-Year Update on Corporate Deferred Prosecution and Non-Prosecution Agreements

-July 10, 2012

U.S. Supreme Court Issues Long-Awaited Decision on the Constitutionality of the Affordable Care Act

-June 29, 2012

In a Ruling with Important Implications for Courts’ Deference to Agencies, U.S. Supreme Court Rejects Department of Labor Position on Overtime for “Outside Sales” Employees

-June 19, 2012

Supreme Court Tightens the Standard for Patent Eligibility Under Section 101 of the Patent Act

-March 21, 2012

2011 Year-End Health Care Compliance Update

-February 6, 2012

The Rising Tide: Recognizing Your Criminal Prosecution Risks Abroad

-December 1, 2011

U.S. Supreme Court Strikes Down Law Regulating Use of Medical Data on Free Speech Grounds

-June 28, 2011

U.S. Supreme Court Decides Scope of Materiality under Federal Securities Laws

-March 25, 2011

2010 Year-End Health Care Compliance Update

-January 14, 2011

Overview of the New Colorado Medicaid False Claims Act

-October 1, 2010

Major Multi-City Takedown Signals Prosecutors’ Continued Focus on Health Care Fraud and Compliance in the U.S.

-July 19, 2010

U.S. Supreme Court to Decide the Scope of Materiality under Federal Securities Laws

-July 15, 2010

The Complexities of Litigating Generic Drug Exclusion Claims in the Antitrust Class Action Context

-April 23, 2010

Federal Circuit Issues Important Decision Construing the Hatch-Waxman Counterclaim and Section viii Carve-Outs

-April 16, 2010

A Summary of the Financial Reporting and Disclosure Implications of the Health Care Reform Legislation

-April 9, 2010

The Impact of U.S. Health Care Reform on Employers

-April 2, 2010

U.S. Health Care Reform Legislation Significantly Expands the False Claims Act

-April 2, 2010

Health Care Compliance in 2009 and Going Forward

-March 1, 2010

2009 Year-End Health Care Compliance Update

-January 14, 2010

Health Care Executive Convicted of Wire Fraud in Connection with Misbranding Allegations

-October 7, 2009

Physician-Consultants: Five Lessons Learned From the Orthopaedic Monitorships

-August 3, 2009

President Obama Signs Legislation Significantly Expanding the Scope of the False Claims Act

-May 26, 2009

Proposed Legislation Amending False Claims Act

-February 26, 2009

Deal Note: Gibson Dunn Represents Apria Healthcare in Its Sale to The Blackstone Group

-October 29, 2008

Deal Note: Gibson Dunn Represents The TriZetto Group in Its Acquisition by Apax Partners

-April 15, 2008